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Abstract
Background: Therapeutic drug monitoring of phenytoin by measurement of plasma concentrations is often
employed to optimize clinical efficacy while avoiding adverse effects. This is most commonly accomplished by
measurement of total phenytoin plasma concentrations. However, total phenytoin levels can be misleading in
patients with factors such as low plasma albumin that alter the free (unbound) concentrations of phenytoin. Direct
measurement of free phenytoin concentrations in plasma is more costly and time-consuming than determination
of total phenytoin concentrations. An alternative to direct measurement of free phenytoin concentrations is use of
the Sheiner-Tozer equation to calculate an adjusted phenytoin that corrects for the plasma albumin concentration.
Innovative medical informatics tools to identify patients who would benefit from adjusted phenytoin calculations
or from laboratory measurement of free phenytoin are needed to improve safety and efficacy of phenytoin
pharmacotherapy. The electronic medical record for an academic medical center was searched for the time period
from August 1, 1996 to November 30, 2010 for patients who had total phenytoin and free phenytoin determined
on the same blood draw, and also a plasma albumin measurement within 7 days of the phenytoin measurements.
The measured free phenytoin plasma concentration was used as the gold standard.
Results: In this study, the standard Sheiner-Tozer formula for calculating an estimated (adjusted) phenytoin level
more frequently underestimates than overestimates the measured free phenytoin relative to the respective
therapeutic ranges. Adjusted phenytoin concentrations provided superior classification of patients than total
phenytoin measurements, particularly at low albumin concentrations. Albumin plasma concentrations up to 7 days
prior to total phenytoin measurements can be used for adjusted phenytoin concentrations.
Conclusions: The results suggest that a measured free phenytoin should be obtained where possible to guide
phenytoin dosing. If this is not feasible, then an adjusted phenytoin can supplement a total phenytoin
concentration, particularly for patients with low plasma albumin.
Background
Recent reports by the Institute of Medicine (IOM) have
publicized the risk of medical errors inherent in Ameri-
ca’s healthcare system [1,2]. To substantially improve
the quality of care, the IOM has called for computerized
physician order entry (CPOE) coupled with clinical deci-
sion support systems (DSS) [2]. Such a combination has
been shown to reduce medical errors [3] and speed
adoption of new patterns of practice [4] as prime
examples of improved quality of care. Still more recent
reports indicate that the processes by which CPOE sys-
tems are implemented are the key to success or failure
in reducing errors [5-7]. The same diligence in imple-
mentation and ongoing review are needed for clinical
DSS to effect change positively.
A significant challenge in clinical care is administra-
tion of phenytoin (PHT) to control seizures. Drug levels
that are low may not control the seizures adequately;
while drug levels that are too high can result in toxic
effects. PHT dosing is challenging because the drug
exhibits non-linear pharmacokinetics, zero-order elimi-
nation, and a multitude of drug-drug interactions [8-11].
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For this reason, drug levels are measured to optimize
dosing, with the usual therapeutic range for plasma total
PHT concentration (PHTtotal) considered to be 10-20
mg/L [12]. PHT is also highly bound to plasma proteins.
It is the free, or unbound, portion of the drug that is
biologically active and which causes both therapeutic
and toxic effects [13]. The therapeutic range for free
PHT plasma concentrations (PHTfree) is generally con-
sidered to be 1-2 mg/L (i.e., PHTtotal divided by 10 or
PHTtotal/10), using an estimated 10% free fraction of
PHT [12].
One factor that causes significant variation in PHT
plasma protein binding is a low plasma albumin level
(hypoalbuminemia), leading to an increased free PHT
fraction, although other factors such as uremia or drug-
drug interactions (e.g., inhibition of phenytoin metabo-
lism by valproic acid) can also alter the free fraction of
PHT [14,15]. In this situation, the usual PHTtotal assay,
which measures both bound and free portions together,
may provide discrepant results relative to the PHTfree
concentration [8,16]. Equations to estimate an adjusted
free PHT (PHTadj_free) using a PHTtotal value exist to
better approximate dose and gauge clinical efficacy. A
common method of predicting the effect of albumin
plasma concentrations on PHT level is the Sheiner-
Tozer equation [14,15], which can be used to calculate
PHTadj_free. If a DSS using this method indicates that
the PHTadj_free is outside the desired target concentra-
tion range in a given individual, then PHT dose may be
adjusted by the clinician and, in addition, the clinician
may decide to monitor PHTfree directly. In this study,
we perform a large retrospective study to determine
how well the PHTadj_free concentrations compare to
direct measurement of PHTfree.
Results and Discussion
There were a total of 1,753 datapoints from 756 patients
that had simultaneous determination of PHTtotal and
PHTfree and also a plasma albumin measured within 7
days of the PHT measurements. As shown in Table 1,
the patient population studied was mostly 15 years or
older (n = 701 out of 756). Roughly equal numbers of
patients were being administered monotherapy with
phenytoin for seizure control (n = 386) as compared to
being prescribed one or more additional anti-epileptic
drugs in addition to phenytoin (n = 370). The most
common co-administered anti-epileptic drugs were leve-
tiracetam (167 patients), phenobarbital (51 patients),
and valproic acid (44 patients) (Table 1). At the time of
blood draw for the initial phenytoin drug level, 263
patients had documentation of seizure within 24 hrs
while 493 patients did not.
Figures 1A and 1B show scatterplots of PHTfree versus
PHTtotal/10 and PHTfree versus PHTadj_free,, respectively,
using only the initial laboratory data for patients (i.e.,
not including repeat measurements for patients).
The Pearson coefficient for the correlations between
PHTtotal/10 and PHTfree was 0.72 and for PHTfree and
PHTadj_free was 0.79. The slope of the regression line
for the relationship between PHTfree versus PHTtotal/10
was statistically different than the line of identity
(slope = 1) (95% confidence interval: 1.045-1.163, P <
0.05 for comparison of slope to 1). In contrast, the
slope of the regression line for the relationship
between PHTfree versus PHTadj_free was not statistically
different from 1 (95% confidence interval: 0.926-1.034).
Additional file 1: Figure S1 (found in Additional file 1)
shows plots similar to Figure 1A and 1B except using
all laboratory data, including repeated measurements
(i.e., using all 1,753 datapoints from 756 patients).
These present very similar relationships to that seen in
Figure 1A and 1B. Additional file 1: Figure S2 presents
Bland-Altman (difference) plots of the data in Figure
1B, both by absolute (Additional file 1: Figure S2A)
and percent bias (Additional file 1: Figure S2B).
Table 1 Study population
Males Females
Total n = 422 n = 334
Age
Average ± SD 52.4 ±
20.9
54.8 ±
21.8
0-12 months n = 12 n = 8
1-14 years old n = 22 n = 13
15-30 years old n = 33 n = 24
31-59 years old n = 192 n = 142
60-79 years old n = 138 n = 108
80 years old or older n = 25 n = 39
Adult inpatient (not ICUa) n = 287 n = 248
Pediatric inpatient (not ICU) n = 19 n = 10
ICU n = 88 n = 59
Emergency room n = 5 n = 5
Primary care clinic n = 4 n = 4
Other outpatient clinic n = 15 n = 8
Monotherapy with phenytoin n = 200 n = 171
One additional anti-epileptic drugsb n = 176 n = 129
Two additional anti-epileptic drugsb n = 38 n = 29
Three or more additional anti-epileptic
drugsb
n = 8 n = 5
No seizures within 24 hrs of phenytoin drug
level
n = 265 n = 228
Seizure(s) within 24 hrs of phenytoin drug
level
n = 157 n = 106
a ICU intensive care unit
b Number of patients administered other anti-epileptic drugs: carbamazepine,
15; clonazepam, 5; diazepam, 10; felbamate, 9; lacosamide, 16; lamotrigine, 30;
levetiracetam, 167; lorazepam, 56; pentobarbital, 14; phenobarbital, 51;
primidone, 6; topiramate 19; valproic acid 44; zonisamide, 13
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Figure 1 Correlation of total, adjusted, and free phenytoin plasma concentrations. (A) Correlation of PHTfree versus PHTtotal/10 for 756
patients is shown. For patients who had multiple phenytoin measurements, only the chronologically first set of PHTfree and PHTtotal/10
measurements is plotted. The solid line is the line of identity, and the dashed line is from linear regression: PHTfree = 0.385 + 1.104 * PHTtotal/10
(R2 = 0.51). The 95% confidence intervals of the intercept is (0.355, 0.415) and for the slope is (1.045,1.163). (B) Correlation of PHTfree versus
PHTadj_free is shown using same source of patient data as in (A). The dashed line is from linear regression: PHTfree = 0.223 + 0.980 * PHTadj_free (R
2
= 0.62). The 95% confidence intervals of the intercept is (0.129, 0.317) and for the slope is (0.926, 1.034)
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Although the PHTadj_free provides a higher Pearson
correlation to PHTfree than PHTtotal/10, the question is
whether a clinician is more likely to make a different
decision when presented with PHTadj_free as opposed to
PHTtotal. This was investigated through the use of con-
tingency tables. Three-by-three contingency tables were
constructed comparing grouping of results for PHTtotal
and PHTfree with respect to their therapeutic ranges
(10-20 mg/L for total phenytoin; 1-2 mg/L for free phe-
nytoin). As Figure 2A and Additional file 1: Figure S3A
shows, PHTtotal frequently is in a lower category than
PHTfree (e.g., PHTtotal below its therapeutic range but
PHTfree within or above its reference range), which
could lead to clinical overdosing of the patient if PHTto-
tal and not PHTfree were used as the basis to guide dos-
ing. The converse situation (PHTfree in a lower category
than PHTtotal) was uncommon. Overall, PHTfree and
PHTtotal were concordant with respect to therapeutic
category less than 50% of the time (43.1% for all data-
points and 46.6% when excluding repeated
measurements).
On the other hand, three-by-three contingency tables
showed that PHTadj_free had improved concordance,
relative to PHTtotal, to PHTfree with respect to therapeu-
tic category (Figure 2B, Additional file 1: Figure S3B).
Similar to the analysis between PHTtotal and PHTfree,
PHTadj_free was more frequently in a lower category to
PHTfree than in a higher category. However, PHTfree
and PHTadj_free were concordant nearly 70% of the time
(68.7% for all datapoints and 69.6% when excluding
repeated measurements), statistically superior to PHTto-
tal (Fisher’s exact test < 0.001).
The concordance data was also broken down into
patients who did or did not have documented seizures
within 24 hours of the blood draw for phenytoin drug
level (Additional file 1: Figure S4) and those on pheny-
toin monotherapy for seizure therapy versus those also
being treated with additional anti-epileptic drugs (Addi-
tional file 1: Figure S5). PHTfree and PHTadj_free were
concordant 73.2% for patient without recent seizures
but only 56.6% for those who had seizures within 24
hours (Fisher’s exact test < 0.001). In contrast, PHTfree
and PHTadj_free were concordant 69.9% for patients on
phenytoin monotherapy and 69.3% for patients on poly-
therapy for seizure control (Fisher’s exact test > 0.05).
We also looked at the three-by-three contingency
table data to see how stable phenytoin measurements
were for patients who had multiple phenytoin measure-
ments over time. In particular, we compared how often,
for a given patient, the temporally next phenytoin mea-
surement fell in the same category in the three-by-three
table as the previous set of measurements. For the data
comparing PHTtotal with PHTfree, the next consecutive
set of phenytoin measurements agreed 53.7% of the
time with the previous measurements (529 out of 997
measurements). For the data comparing PHTadj_free with
PHTfree, the next consecutive set of phenytoin measure-
ments agreed 46.9% of the time with the previous mea-
surements (468 out of 997 measurements). These data
may reflect the predominantly inpatient population stu-
died, where shifts in phenytoin dosing and also changes
in other factors (e.g., concomitant) were needed for
patients with unstable clinical status.
The difference between PHTtotal/10 and PHTfree was
also examined in relation to plasma albumin concentra-
tion (Figure 3A, Additional file 1: Figure S6A). The dis-
crepancy between PHTfree and PHTtotal/10 is most
pronounced at low plasma albumin concentrations,
where the ratio of PHTfree to PHTtotal would be
expected to be higher. However, there are clearly many
examples of marked discrepancies between PHTfree and
PHTtotal/10 even when the plasma albumin concentra-
tions is within the age-specific reference range. PHTfree
is generally greater than PHTtotal/10 throughout all ages
with examples of patients showing differences of > 2
mg/L evident throughout all age groups. The slope of
the regression line in Figure 3Awas significantly differ-
ent from 0 (i.e., null hypothesis of no relationship; 95%
confidence interval; -2.37 to -1.90; P < 0.05). In contrast,
the difference between PHTfree and PHTadj_free shows
little relationship with respect to plasma albumin con-
centration (Figure 3B, Additional file 1: Figure S6B),
with the slope of the regression line in Figure 3B show-
ing no significant difference from 0 (95% confidence
interval: -0.0649 to 0.0691).
The difference between PHTtotal/10 and PHTfree was
also examined in relation to patient age (Figure 4A,
Additional file 1: Figure S7A), which revealed no statisti-
cally significant difference of the slope of the regression
line in Figure 4A from 0 (95% confidence interval:
-0.056 to 0.064). A similar finding was noted between
the difference between PHTfree and PHTadj_free (Figure
4B, Additional file 1: Figure S7B). The slope of the
regression line in Figure 4B showed no statistically sig-
nificant difference from 0 (95% confidence interval:
-0.053 to 0.057).
A series of analyses were also done to try to under-
stand what additional factors might influence how well
PHTadj_free predicts PHTfree, using plots of the difference
between PHTfree and PHTadj_free and various indepen-
dent variables (Figure 5; note that the statistical analyses
in 5A-5D were four separate procedures). There is little
influence of patient gender (Figure 5A) or days between
albumin and PHTfree/PHTtotal measurements (Figure 5B)
on the difference between PHTfree and PHTadj_free.
There was, however, a significant effect of patient loca-
tion at time of PHT measurements (Figure 5C), with the
deviation between PHTfree and PHTadj_free highest in
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Figure 2 Clinical decision using total phenytoin or adjusted phenytoin compared to measured free phenytoin. (A) The data is derived
from three-by-three contingency tables comparing grouping of PHTtotal and PHTfree into lower than therapeutic reference range (L), within
therapeutic reference range (T), and higher than therapeutic reference range (H). For the three bar graphs on the left, PHTtotal would tend to
lead to underdosing relative to the PHTfree. For the three bar graphs in the center, PHTtotal and PHTfree are concordant. For the three bar graphs
on the left, PHTtotal would tend to lead to overdosing relative to PHTfree. For patients who had multiple phenytoin measurements, only the
chronologically first set of concentrations available is plotted. The data is from 756 patients. (B) Similar design as in (A) except that PHTadj_free
(using the Sheiner-Tozer equation) is compared to PHTfree. The data is from 756 patients
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Figure 3 Variation of total phenytoin, adjusted phenytoin, and free phenytoin with respect to plasma albumin concentration. (A)
Variation of the difference between PHTtotal/10 and PHTfree with respect to plasma albumin concentration. All data is from chronologically first
phenytoin measurements in 756 patients. The dashed line is from linear regression: [PHTtotal/10 - PHTfree] = -2.136 + 0.477 * [albumin
concentration] (R2 = 0.19). The 95% confidence intervals of the intercept is (-2.37, -1.90) and for the slope is (0.406, 0.549). (B) Variation of the
difference between PHTfree and PHTadj_free with respect to plasma albumin concentration using same source of patient data in (A). The dashed
line is from linear regression: [PHTfree - PHTadj_free] = 0.0838 + 0.0021*[plasma albumin] (R
2 = 0.004). The 95% confidence intervals of the intercept
is (-0.138, 0.305) and for the slope is (-0.0649, 0.0691)
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Figure 4 Variation of total phenytoin, adjusted phenytoin, and free phenytoin with respect to patient age. (A) Variation of the difference
between PHTtotal/10 and PHTfree with respect to patient age. All data from chronologically first phenytoin measurements in 756 patients. The
dashed line is from linear regression: [PHTtotal/10 - PHTfree] = -0.394 + 0.0038*(patient age) (R
2 = 0.01). The 95% confidence intervals of the
intercept is (-0.464, -0.372) and for the slope is (-0.056, 0.064). (B) Variation of the difference between PHTfree and PHTadj_free with respect to
patient age is shown using same source of data as in (A). The dashed line is from linear regression: [PHTfree - PHTadj_free] = 0.0838 + 0.0021 * age
(R2 = 0.004). The 95% confidence intervals of the intercept is (-0.0072, 0.174) and for the slope is (-0.053, 0.057)
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adult inpatient (non-ICU) and ICU units. In the inpati-
ent settings, PHTfree was significantly greater than
PHTadj_free. PHTfree - PHTadj_free did not vary signifi-
cantly with the year in which the phenytoin measure-
ments were performed (Figure 5D), suggesting that
changes in clinical laboratory instrumentation and
assays over the years of the retrospective analysis did
not cause any changes in PHTfree, PHTtotal, or plasma
albumin concentrations that might systematically impact
the relation of PHTfree to PHTadj_free.
Figure 5 Variation of the difference of PHTfree and PHTadj_free with respect to various independent variables. (A) Distribution of the
difference between PHTfree and PHTadj_free separated between males and females. Each dot represents a single timepoint of data with a
total of 1,020 datapoints from male patients and 733 datapoints from female patients. The solid horizontal lines indicate the mean difference.
There was no significant difference between males and females (unpaired t-test > 0.05). (B) Distribution of the difference between PHTfree and
PHTadj_free separated by the days in between the albumin and total phenytoin measurements (that allowed for PHTadj_free calculation). Each dot
represents a single timepoint of data with a total of 1,753 datapoints (559 datapoints for 0 days difference between albumin and PHTtotal
determination, 290 for 1 day difference, 215 for 2 days difference, 190 for 3 days difference, 152 for 4 days difference, 103 for 5 days difference,
112 for 6 days difference, and 132 for 7 days difference). The solid horizontal lines indicate the mean difference. There was no significant
difference across days between albumin and phenytoin measurements (ANOVA P value > 0.05). (C) Distribution of the difference between
PHTfree and PHTadj_free separated into categories of patient location at time of laboratory ordering of PHTtotal and PHTfree. ‘Adult inpatient’ and
‘Peds inpatient’ encompass all inpatient locations excluding intensive care units (ICUs), with adult defined as age 15 or older. ‘All other locations’
encompasses outpatient clinics, emergency room, and scheduled draws at hospital phlebotomy stations. (D) Distribution of the difference
between PHTfree and PHTadj_free separated into years in which the laboratory measurements were performed. There was a significant effect of
patient location at time of PHT measurements (ANOVA P value < 0.0001)
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Since its initial development, the Sheiner-Tozer equa-
tion has been widely used to assist therapeutic drug
monitoring of phenytoin [14,15]. It is even included in
the MedMath module of Epocrates™ software (regis-
tered trademark of Epocrates, Inc., San Mateo, CA,
USA,). Despite this widespread use, there has been con-
siderable controversy over whether inaccuracies in the
model justify its use or not. Some authors have argued
that since PHTfree levels may not be readily available,
the adjustment in cases of known hypoalbuminemia
provides better guidance in dosing than the total PHT
level obtained in the usual assay used for therapeutic
drug monitoring [9,15,17]. In a population of “critically
ill neurosurgical patients”, Mlynarek et al. concluded
that the Sheiner-Tozer equation provided “an unbiased,
precise clinical estimate” in cases where the PHTfree
level “is unavailable or impractical” [17]. For rural clinics
in sub-Saharan Africa where malnutrition and AIDS are
frequent, Fedler and Stewart concluded that the cor-
rected value should be reported rather than the total
phenytoin [9]. On the other hand, two reports from uni-
versity hospital settings concluded that because of the
inaccuracies of the model, the Sheiner-Tozer equation
should not be used [14,18]. Other studies have recom-
mended that PHTtotal not be used at all, and that
PHTfree alone be used for drug monitoring of PHT [19].
In our study, PHTadj_free provides a better estimate of
PHTfree (relative to reference range) than PHTtotal. Pre-
vious studies have focused on more limited sample sizes
and patient populations [14,17,18,20]. Our study
included a population of mainly adults in the inpatient
setting, including patients with refractory epilepsy and/
or who were on multiple other anti-epileptic medica-
tions in addition to phenytoin. The linear regression
lines relating PHTfree to PHTadj_free have a slope close to
1 with only a slight negative bias (~0.2-0.3 mg/L) of
PHTadj_free relative to PHTfree. However, we did demon-
strate that the greatest bias between PHTfree and
PHTadj_free was seen in hospital inpatients, possibly due
to other factors (e.g., concomitant drugs, organ failure)
that can impact PHT pharmacokinetics.
In the university hospital setting, the cost to the clini-
cal laboratory to perform the PHTfree assay can be
almost twice the cost of the PHTtotal assay. In addition,
the PHTfree assay process includes an extra ultra-filtra-
tion step that requires centrifugation [13,21]. Because of
these extra steps, and for quality control, PHTfree assays
for a given day may be held and run in one or more
batches during the day to limit labor-intensive steps.
This contrasts with PHTtotal levels that may run
throughout the day on automated instrumentation with-
out need for separate processing steps. Thus, there may
be a delay in receiving the PHTfree results compared to
the availability of the PHTtotal result on the same
sample. In the case of a smaller hospital, where it may
be longer until the batch of PHTfree samples is accumu-
lated and processed, or if PHTfree levels are sent to a
reference lab instead of done in house, the time dispar-
ity could be even greater. However, the added costs of
the PHTfree assay should be assessed in context with the
risks of suboptimal phenytoin dosing (e.g., poor seizure
control, toxicity, etc.).
Most of the “rule of thumb” equations in common use
presume that the clinician is doing the calculation by
hand or calculator, using a few readily available results
to derive additional knowledge not directly reported. A
modern electronic health record (EHR) with integrated
DSS can provide added value for the clinician by doing
these calculations automatically and posting the results,
saving time and eliminating errors in calculation. One of
the authors has taken this approach at the University of
Pittsburgh Medical Center (UPMC) by developing and
implementing rules to provide Anion Gap, Adjusted
Sodium for hyperglycemia, and Adjusted Calcium for
hypoalbuminemia, in addition to an Adjusted Phenytoin
Rule. In all cases, interpretive data is attached to the
result to further assist the clinician in decision making.
Education of clinicians is important to emphasize the
difference and limitations of both calculated and directly
measured parameters.
There are several main limitations to the analysis pre-
sented in this paper. First, the patient population con-
tains far more adults than pediatric patients.
Consequently, the results are mostly applicable to adult
patients. Future studies targeted at children, especially
very young children, are needed. Second, the majority of
datapoints arise from patients in inpatient units (includ-
ing intensive care units) with lesser availability of data-
points arising from patients in outpatient clinics or the
emergency room. However, the sample size of this study
exceeds that of previous studies and contains a patient
population that likely is similar to that analyzed by clini-
cal laboratories at many academic medical centers, and
has produced results comparable to other similar studies
of academic medical center patient populations [14,18].
Lastly, although nutritional status was not examined in
detail, it is likely that most patients in the study were
well-nourished and thus the findings are most applicable
to other well-nourished populations.
Addressing the question of whether a better model
than the Sheiner-Tozer equation could be implemented
is the subject of additional analysis and development
currently underway. The analysis reported here, along
with the capabilities of the EHR and DSS, suggest addi-
tional possibilities to enhance the medical knowledge
available to clinicians at the point of care. In addition to
hypoalbuminemia, there are other factors that can influ-
ence binding of PHT and alter the free PHT fraction
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[14]. With a “rule of thumb” type calculation, it is prohi-
bitive to track these additional factors and perform the
calculations they would entail by hand or using a non-
programmable calculator. However, given the extensive
data available electronically in the EHR and the logic
capabilities of a modern DSS, it may become practical
to implement far more complex models than those tra-
ditionally used in clinical practice. With knowledge dis-
covery tools, the data available in the EHR database
provide a substrate for increasingly sophisticated mod-
els. The development and testing of a model that pre-
dicts free phenytoin better than done by the Sheiner-
Tozer model is the focus of additional research by the
authors.
Conclusions
In this study, the standard formula for calculating an
estimated (adjusted) phenytoin level more frequently
underestimates than overestimates the free phenytoin
relative to the respective therapeutic ranges. Estimated
free phenytoin concentrations predicted measured free
phenytoin concentrations better than total phenytoin
measurements, although there is considerable scatter in
the data. The results suggest that a measured free phe-
nytoin should be obtained where possible to guide phe-
nytoin dosing. If this is not feasible, then an adjusted
phenytoin can supplement a total phenytoin concentra-
tion, with concurrent education of physicians as to the
limitations of the adjusted phenytoin prediction.
Methods
The project had Institutional Review Board approval
from the University of Iowa. The electronic medical
record (Epic, Epic Systems Inc., Madison, WI, USA) was
searched for the time period from 8/1/1996 to 11/30/
2010 for patients with PHTtotal and PHTfree determined
on the same blood draw and also a plasma albumin
determined within the past seven days of the phenytoin
measurements, with PHTtotal, PHTfree, plasma albumin
concentration, patient age, location (e.g., inpatient, out-
patient, etc.) and gender downloaded. Chart review was
performed to ascertain other anti-epileptic medications
used in addition to phenytoin, and also whether patients
had seizures within 24 hrs of the phenytoin drug level.
During the entire time period of the retrospective analy-
sis, the University of Iowa Hospitals and Clinics central
clinical laboratory used the same assays to measure
plasma phenytoin and free phenytoin on Roche Diag-
nostics (Indianapolis, IN, USA) P module automated
chemistry analyzers. The total phenytoin measurement
was performed using the Roche Phenytoin CEDIA
(cloned enzyme donor immunoassay) method according
to manufacturer’s instructions. The free phenytoin assay
was the Siemens Syva Emit 2000 Phenytoin Assay, an
immunoassay adapted for use on the Roche modular P
analyzer [22]. Specifically, plasma specimens were first
allowed to equilibrate to room temperature. Then 500
μL of sample was applied to the sample reservoir of an
assembled Amicon micropartition system MPS-1 (Milli-
pore, Billerica, MA, USA), making sure no air was
trapped in the reservoir. The reservoirs were then
capped and centrifuged at 3400 rpm for 20 min using a
centrifuge equipped with an angle head rotor. The ultra-
filtrate was then transferred to a sample cup and ana-
lyzed. The characteristics of the study population are
summarized in Table 1.
The Sheiner-Tozer equation is expressed as:
PHTadj_free = [PHTtotal/{(0.2 × Albumin) + 0.1)}]/10,
with PHT plasma concentrations in units of mg/L and
albumin plasma concentrations (Albumin) in units of g/
dL. This assumes an estimated free fraction of PHT of
10%.
For comparison analysis, PHTfree was considered the
reference method (comparator). Comparisons of
whether PHTtotal, PHTfree, and PHTadj_free results fell
within the same range compared to their respective
therapeutic ranges gave an indication of the accuracy of
the prediction models. Chi-squared analysis of decision
making and ANOVA were performed using SPSS ver-
sion 13.0 (SPSS, Inc., Chicago, IL, USA). Linear regres-
sion and Pearson correlation analysis were carried out
in EP Evaluator release 9 (Data Innovations, South Bur-
lington, VT, USA). Statistical comparison of linear
regression utilized two-tailed t tests in EP Evaluator.
Additional material
Additional file 1: Figure S1 (correlation of PHTfree versus PHTtotal/10
and PHTfree versus PHTadj_free), Figure S2 (Bland-Altman plots),
Figure S3 (three-by-three contingency tables of PHTtotal and
PHTfree), Figure S4 (three-bv-three contingency tables of PHTadj_free
and PHTfree comparing those with recent seizures or no recent
seizures), Figure S5 (three-bv-three contingency tables of PHTadj_free
and PHTfree comparing those on phenytoin monotherapy versus
polytherapy with other anti-epileptic drugs), Figure S6 (effect of
albumin concentration on free phenytoin estimation), and Figure
S7 (effect of patient age on free phenytoin estimation).
Acknowledgements
We thank the staff of the Clinical Chemistry laboratory (particularly Jeff
Kulhavy) for help in understanding laboratory practices and history of
phenytoin and free phenytoin analysis. MDK thanks the Department of
Pathology (Dr. Michael Cohen, Department Executive Officer) for providing
research funding.
Author details
1Department of Pathology, University of Iowa Hospitals and Clinics, Iowa
City, IA 52242, USA. 2Department of Physical Medicine and Rehabilitation,
University of Pittsburgh, Pittsburgh, PA 15213, USA. 3Baptist Health South
Florida, Miami, FL 33176, USA.
Krasowski and Penrod BMC Medical Informatics and Decision Making 2012, 12:7
http://www.biomedcentral.com/1472-6947/12/7
Page 10 of 11
Authors’ contributions
MDK and LEP were both involved in the study concept and design, analysis
and interpretation of the data. MDK drafted the manuscript. Both authors
have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 July 2011 Accepted: 14 February 2012
Published: 14 February 2012
References
1. Kohn LT, Corrigan J, Donaldson MS: To err is human: building a safe health
system Washington, DC: National Academy Press; 2000.
2. (U.S.) IoM: Committee on Quality of Health Care in America. Crossing the
quality chasm: a new health system for the 21st century Washington, DC:
National Academy Press; 2001.
3. Bates DW, Cohen M, Leape LL, Overhage JM, Shabot MM, Sheridan T:
Reducing the frequency of errors in medicine using information
technology. J Am Med Inform Assoc 2001, 8:299-308.
4. Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW: Effects
of computerized physician order entry on prescribing practices. Arch
Intern Med 2000, 160:2741-2747.
5. Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL:
Role of computerized physician order entry system in facilitating
medication errors. JAMA 2005, 293:1197-1203.
6. Berger RG, Kichak JP: Computerized physician order entry: helpful or
harmful? J Am Med Inform Assoc 2004, 11:100-103.
7. Ash JS, Berg M, Coiera E: Some unintended consequences of information
technology in health care: the nature of patient care information
system-related errors. J Am Med Inform Assoc 2004, 11:104-112.
8. Dasgupta A: Usefulness of monitoring free (unbound) concentrations of
therapeutic drugs in patient management. Clin Chim Acta 2007, 377:1-13.
9. Fedler C, Stewart MJ: Plasma total phenytoin: a possibly misleading test
in developing countries. Ther Drug Monit 1999, 21:15-160.
10. Martin E, Tozer TN, Sheiner LB, Riegelman S: The clinical pharmacokinetics
of phenytoin. J Pharmacokinet Biopharm 1977, 5:579-596.
11. Perucca E: Clinically relevant drug interactions with antiepileptic drugs.
Br J Clin Pharmacol 2006, 61:246-255.
12. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI,
Tomson T, Perucca E: Antiepileptic drugs - best practice guidelines for
therapeutic drug monitoring: a position paper by the subcommission on
therapeutic drug monitoring, ILAE Commission on Therapeutic
Strategies. Epilepsia 2008, 49:1239-1276.
13. Dasgupta A: Clinical utility of free drug monitoring. Clin Chem Lab Med
2002, 40:986-993.
14. Banh HL, Burton ME, Sperling MR: Interpatient and intrapatient variability
in phenytoin protein binding. Ther Drug Monit 2002, 24:379-385.
15. Profeta LM, Bradbury K, Mehl B: Pharmacokinetic considerations in
phenytoin pharmacotherapy: preventing overdoses and underdoses. Mt
Sinai J Med 1995, 62:312-314.
16. Chan K, Beran RG: Value of therapeutic drug level monitoring and
unbound (free) levels. Seizure 2008, 17:572-575.
17. Mlynarek ME, Peterson EL, Zarowitz BJ: Predicting unbound phenytoin
concentrations in the critically ill neurosurgical patient. Ann
Pharmacother 1996, 30:219-223.
18. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL: Correlation
and prediction of phenytoin protein binding using standard laboratory
parameters in patients after renal transplantation. Ther Drug Monit 2001,
23:263-267.
19. Burt M, Anderson DC, Kloss J, Apple FS: Evidence-based implementation
of free phenytoin therapeutic drug monitoring. Clin Chem 2000,
46:1132-1135.
20. Hong JM, Choi YC, Kim WJ: Differences between the measured and
calculated free serum phenytoin concentrations in epileptic patients.
Yonsei Med J 2009, 50:517-520.
21. McMillin GA, Juenke J, Dasgupta A: Effect of ultrafiltrate volume on
determination of free phenytoin concentration. Ther Drug Monit 2005,
27:630-633.
22. Roberts WL, Annesley TM, De BK, Moulton L, Juenke JM, Moyer TP:
Performance characteristics of four free phenytoin immunoassays. Ther
Drug Monit 2001, 23:148-154.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6947/12/7/prepub
doi:10.1186/1472-6947-12-7
Cite this article as: Krasowski and Penrod: Clinical decision support of
therapeutic drug monitoring of phenytoin: measured versus adjusted
phenytoin plasma concentrations. BMC Medical Informatics and Decision
Making 2012 12:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Krasowski and Penrod BMC Medical Informatics and Decision Making 2012, 12:7
http://www.biomedcentral.com/1472-6947/12/7
Page 11 of 11
